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Following mitogenic or antigenic stimulation in vitro, T lymphocytes are induced
to express a large number of genes, including those encoding lymphokines and IL-2
receptors (1-4). The induction of lymphokine genes is particularly sensitive to the
immunosuppressive drug cyclosporin A [CSA] ' (1, 5-8). Since responsiveness to IL-
2 is induced in the presence ofCSA, the loss ofgrowth factors and otherlymphokines
is thought to be the main mechanism for the immunosuppressive effects of CSA
in vivo (9). However, much of the work on CSA has involved in vitro approaches.
Molecular approaches have not been used in vivo, and recent evidence suggests that
CSA does not even block DNA synthesis in mice or rats (10, 11). I have looked into
these unknowns using a protocol wherein the injection of allogeneic cells induces
the formation of cytolytic T cells in vivo (10, 12, 13). This response involves IL-2,
since it is blocked by a neutralizing anti-IL-2 antibody (13). I have been able to docu-
ment the induction of lymphokine genes in vivo and to determine that CSA can
inhibit proliferative responses in mice whether allogeneic cells or mitogens are the
stimuli.
Materials and Methods
Materials.
￿
[CxD2]F, and B6xD2 mice were obtained from Trudeau Institute (Saranac
Lake, NY) and Con A from Miles Laboratories Inc. (Elkhart, IN). Ascites containing anti-
CD3 mAb was obtained by injecting 2 x 10' 2C11 anti-CD3 hybridoma cells (14) in-
traperitoneally into pristane-primed CxD2 F, mice. Drs. J. F Borel and B. Ryffel (Sandoz
Pharmaceutical, Basel, Switzerland) and Sandoz (East Hanover, NJ) generously supplied CSA.
CSA Treatment.
￿
Mice were treated orally with CSA (30 mg/kg/day). Mice were immunosup-
pressed with CSA 48 h before treatment with alloantigens or mitogens. CSA levels in serum
were determined to be 900-3,500 ng/ml using an RIA kit (Sandoz, Basel, Switzerland).
Stimulation of Popliteal Lymph Nodes and Cell Preparations.
￿
Popliteal lymph nodes were in-
jected as described (13). 30 pl of PBS containing 107 B6xD2 spleen cells was injected into
the left hind foot pad of [CxD2]F, recipients. As a control, the right hind foot pads were
injected with 30 Wl of PBS or 30 pl containing 107 syngeneic cells. Alternatively, hind foot
pads were injected with 50 pl ofCon A (1 mg/ml) or 30 pl of2C11 ascites fluid. At the appro-
priate time, the draining popliteal lymph nodes were removed, and cell suspensions were
prepared. 106 cells/ml were left unstimulated or were stimulated with graded doses of rIL-2
(1.2 x 106 U/mg; Biogen, Cambridge, MA). Proliferation and response to IL-2 were assessed
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on triplicate cultures of 105 cells that were pulsed for 4 h with 1.5 ACi [3H]TdR either at
0-4 or 24-28 h of culture.
Northern Blot Analysis.
￿
The draining lymph nodes (8-10 nodes for each time point) were
carefully dissected, cleaned of connective tissues, and immediately immersed in 4 M guani-
dine isothiocyanate. Nodes were disrupted by sonication using a Polytron, and total RNA
was isolated by centrifugation through a cesium chloride cushion (15, 16). 10 Wg of RNA
was electrophoresed on a 1% or 1.5 17o agarose-formaldehyde gel. RNA was transferred by
vacuum to gene screen filters (New England Nuclear, Boston, MA) and crosslinked by UV
(1200 AJ) to the filters for hybridization with 32P-labeled cRNA probes.
Preparation ofcRNA Probes.
￿
The Pst I fragments from the cDNA IFN-.y clone pms10 (17),
and pro IL-2R-1 (18) were subcloned into pIBI-30 vector (Institute of Biotechnology Inc.,
New Haven, CT). The RSA fragment of the cDNA pm IL-2 (19) was adapted with ECO
RI linkers and subcloned into the ECO RI site of Bluescript KSII` (Stratagene, La Jolla,
CA). The recombinant plasmids were linearized and radioactive sense and antisense probes
were generated using T3 and T7 polymerase and [35S]UTP or [32P]CTP (NEN DuPont Co.,
Wilmington, DE).
In Situ Hybridization.
￿
Lymph node cell suspensions were cytocentrifuged on coated glass
slides as described (20); alternatively, lymph nodes were embedded in OTC and frozen cryostat
sections were applied to 0.5°Jo gelatin slides. Cells and sections were fixed for 20 min in 4%
paraformaldehyde at room temperature and processed with radiolabeled antisense and sense
RNA probes as described (20).
Immunocytochemistry and Autoradiography.
￿
Lymph node cell suspensions were pulsed with
[3H]TdR for 2 h. Cells were washed three times, resuspended in PBS, and cytospun. Cells
were fixed in 2% buffered glutaraldehyde and dehydrated. Alternatively, [3H]TdR (25,uCi)
was injected intraperitoneally into mice. After 2 h popliteal lymph nodeswere harvested and
tissues were embedded with OTC (Tissue Tek). Serial 6-Am sections were cut in a cryostat
and picked up on multiwell slides (Carlson Scientific Inc., Peotone, IL), air-dried, and stored
at -20°C . Sections were dried at 37°C, fixed with acetone (10 min at room temperature),
and stained with mAb culture supernatants obtained via the American Type Culture Collec-
tion (B220 TIB-146 for B cells and L3T4 TIB-207 for T cells). After washing, sections were
incubated with peroxidase-labeled mouse anti-rat IgG. The bound anti-Ig was visualized
by the immunoperoxidase Vectastain ABC kit (Vector Laboratories). Dehydrated slides were
dipped in NTB-2 emulsion [Eastman Kodak, Rochester, NY). After various times, the slides
were developed in Kodak D19 for 5 min, rinsed in tap water, and fixed for 5 min in Kodak
fixer A.
Results
Effects of CSA on the Proliferative Responses Induced by Foreign Cells In Situ.
￿
Popliteal
lymph nodes were stimulated by the administration of allogeneic spleen cells (H-2'x'
cells into the footpads of H-2d recipients), in the presence or absence of the im-
munosuppressive agent, CSA. The draining lymph nodes were removed at daily in-
tervals, and the cell suspensions were assessed for DNA synthesis before and after
in vitro stimulation with rIL-2. As seen in Fig. 1, A and B (e), an increase in DNA
synthesis was observed in lymph node cells taken 48-72 h after exposure to allogeneic
leukocytes. This proliferative response was much reduced after treatment with CSA
(Fig. 1 A, compare " with A).
The administration of allogeneic cells also increased the responsiveness of the
draining lymph node cells to exogenous IL-2 (Fig. 1 B O, A). However, the develop-
ment of IL-2 responsiveness was not reduced by CSA. Only low doses of IL-2 were
required to stimulate DNA synthesis (Fig. 1 C), suggesting the presence of func-
tional high affinity IL-2 receptors.
We also isolated popliteal nodes from mice that had been exposed to mitogens,
comparing these with injections of syngeneic or allogeneic cells. Mitogens, like al-E
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FIGURE 1.
￿
Effect of CSA on the proliferative responses of popliteal lymph node cells activated
in vivo. 10' B6xD2 (H-2bxd) spleen cells were injected into the hind footpads of CxD2 mice
(H-2d"d) that were treated (A, A) or not treated (O, ") with CSA. The draining nodes were
removed at the indicated time points andcell suspensions were prepared. (A) 105 cells were im-
mediately pulsed for 4 h with [ H]TdR to measurespontaneous proliferation. (B) 105 cells were
cultured with/without IL-2 (10 U/ml) for 24 h and then pulsed with [3H]TdRfor 4h. (C) After
72 h of activation by alloantigen in vivo, 105 lymph node cells were cultured with different con-
centrations of IL-2 for 24 h and then pulsed with [3H]TdR for 4 h.
loantigens, increased the level ofDNA synthesis in the draining lymph node, and
this increase was suppressed 60-80% if the animals had been given CSA (Table I,
left side). Each stimulus also resulted in a heightened T cell response to IL-2 in
vitro; but the enhanced responsiveness was largely resistant to CSA (Table I, right
side). These results indicated that CSA was having similar effects in vivo to those
observed in vitro, i.e., IL-2 responsiveness was being induced but DNA synthesis
was blocked (1, 21).
Identification ofProliferating Cells in Lymph Nodes Stimulated In Situ.
￿
To better iden-
tify and enumerate cells that were responding to allogeneic or mitogenic stimulation,
we administered [3H]TdR in vivo, or for 2 h in vitro immediately after isolation
TABLE I
Response of Lymph Node Cells to IL-2 After In Vivo Stimulation
Anti-CM mAb (30 pl of 2C11 ascites fluid), Con A (50 kg), B6xD2 (107) cells, and CxD2 F1 (107) cells
were injected in the hind foot pad of CxD2 F1 mice. The mice were or were not treated with CSA. After
48 h, the draining lymph nodes were collected andcell suspensions were prepared. Cells were plated at 106
cells/ml in the presence or absence of rIL2 (10 U/ml). After 24 h of culture, proliferation was determined
in 100-pl aliquots by adding [3H]TdR for 4 h.
Stimulus
in vivo No
Without
CSA
cpm
IL-2
With CSA No
With IL-2 (10
CSA
cpm
U/ml)
With CSA
None 800 t 30 ND 2,430 t 70 ND
Anti-CD3 4,616 t 150 939 t 7 32,322 t 1,100 24,661 t 800
Con A 7,248 t 170 2,592 t 80 38,216 f 1,000 29,438 t 750
Allogeneic cells 7,500 t 130 2,346 t 54 58,286 f 1,300 51,587 t 1,200
Syngeneic cells 1,583 t 100 1,300 t 90 16,768 t 750 14,685 t 1,000536
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ofthedraining lymphnode cells. The specimenswere processedfor autoradiography.
2-3% ofthe cellswere labeled inthe suspensions from unstimulated mice, but much
larger percentages were synthesizing DNA after stimulation with allogeneic cells
or mitogens, especially at later time points (Table II). When the cells were treated
with either anti-13220 (B cell-specific) oranti Thy-1 (T cell-specific) antibodies and
complement just before measuring [3H]TdR uptake, the proliferating cells were
found to be T cells (Fig. 2).
When [3H]TdRwas given in vivo to mice, an increase in [3H]TdR labeled profiles
was apparent in autoradiograms ofnodes that had been stimulated with allogeneic
cells. When the lymph node sections were stained with anti-B or anti-T cell mAbs
and processed for autoradiography, the labeled cells were for the most part in the T
areas (para and deep cortex with many CD4+ 13220 - cells) ofthe lymph node (Fig. 3).
The effect ofCSA on all oftheabove parameters was monitored. CSAdiminished
but did not completely block [3H]TdR uptake in lymph node cells that had been
stimulated in vivo with allogeneic cells or mitogens (Table II). CSA also reduced,
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TABLE II
(3HJTdR-labeled Lymph Node Cells after In Vivo Stimulation
107 allogeneic cells (B6xD2 mice), anti-CD3 mAb (30 Al 2C11 ascites), or Con
A (50 pg) were injected in the hind foot pads of CxD2 FI mice. At the indicat-
ed times, the draining lymph nodes were collected and cell suspensions were pre-
pared. Cells were pulsed for 2 h with 0.5 1Xi of [3H]TdR and processed as
described in Materials and Methods.
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FIGURE 2 . Characterization of
the proliferating lymphocytes after
alloantigen stimulation in vivo. Al-
logeneic spleen cells were injected
into the hind foot pads ofmice that
were treated or not treated with
CSA. After 72 h the draining lymph
nodes were removed and cells sus-
pensions were prepared. Cells were
left untreated or depleted of B cells
by treatment with anti-13220, or
depleted of T cells by treatment
with Thy-1 and complement. 105
cells were cultured with IL-2 (10
U/ml) for 24 h and then pulsed with
[3H]TdR for 4 h.
Stimulus in vivo
Percent of
24 h
labeled cells
48 h
Uninjected 2.5 2 .0
Allo 7 .6 25 .0
Allo CSA 2 .9 7 .8
Anti CD3 ND 40.0
Anti CD3 CSA ND 15 .0
Con A 35 .0 41 .8
Con A CSA 3 .2 8.8GRANELLI-PIPERNO
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FIGURE 3 .
￿
Localization of cells synthesizing DNA in situ . Mice were stimulated with alloan-
tigen and at 48 h, [3H]TdR was injected. 2 h later lymph nodes were taken and sections were
prepared for immunolabeling with mAb to B orT cells followed by peroxidase mouse anti-rat
Ig anddiaminobenzidine staining. Shownhere is theB220mAb to B cells (leftpanels) andaCD4
to T cells (right panels) . After dehydration, sectionswere processed for autoradiography . Note that
the [3H]TdRlabeled cells are predominantly confined to the Tarea, which in these sections are
the areas ofcortex with fewB220' cellsandmany CD4' cells . (Top) Representative sections from
control mice ; (middle) sections from mice stimulated with alloantigen; and (bottom) sections from
mice stimulated with allo in the presence ofCSA.
but did not eliminate the number of labeled cells in lymph node sections (Fig . 3) .
For example, an averageof 85 labeled cellswere scored onlymphnode sections from
uninjected mice, 390-410 on lymph node sections from alloantigen-injected mice
and 140-160 on sections from CSA-treated mice . At this time we do not know if
the cells that incorporated [3H]TdR in the presence of CSA progressed normally
through the cell cycle or were arrested in S phase because ofalack of lymphokine .
Expression of T Cell Activation Genes after In Vivo Stimulation.
￿
RNA was extracted538
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fromlymph nodes at different time points after allogeneic stimulation and analyzed
by Northern blot . A strong signal for IFN-gmRNAs was noted upon administra-
tion ofalloantigen, with maximal expression at 22-36h (Fig . 4) . By 48 h, transcripts
were no longer detected (Fig. 4) . The induction of transcripts was dependent upon
the dose of alloantigen from 1 to 10 x 106 allogeneic spleen cells (Fig. 5) . Stimula-
tion with syngeneic cells, even at high concentrations, didnot induce IFN-g (see below) .
Injection of allogeneic cells induced IL-2 mRNA as well (Figs . 4 and 5) . With
the IL-2 probe used, two bands were detected : a fast migrating band at 1 kb corre-
sponding to the transcript for IL-2 that is present only in stimulated cells both for
FIGURE 4.
￿
Time course ofmRNA accumu-
lation in the draininglymph node. Allogeneic
spleen cells were injected into the hind
footpads ofmice. The draining nodes were re-
moved at the indicated times and RNA was
extracted . 10 pgofRNA was separated on 1%
agarose-formaldehyde gel and hybridized with
32p-labeled probes .
FIGURE 5 .
￿
Lymphokine mRNA expression . Effect of
the number allogeneic cells injected. The hind footpads
ofmice, either immunosuppressed ornot with GSA, were
injected with graded doses ofallogeneic spleen cells. After
24 h, lymph nodes were collected and total RNA was
separated on 1% agarose-formaldehyde gel and hybrid-
ized with 32P-labeled probe.GRANELLI-PIPERNO
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lymph nodes and spleen, and a slow migrating band (1.35 kb) that is present both
in unstimulated and stimulated cells (Figs . 4 and 5) . Removal of theDNAtemplate
after transcription of the RNA probe eliminated the 1.35-kb band . Routinely, the
cRNA probe was used without removing the DNA template because the 1.35-kb
band served as an internal control, demonstrating that the same amount ofRNA
was loaded in each lane . As was seen for IFN-,y, IL-2 expression was observed at
22-36 h (Fig. 4) . P55 IL-2RmRNA was also induced upon injection of allogeneic
cells (Fig . 4) .
The experiments were also conducted usingmitogens as the stimuli in vivo. Both
ConAand anti-CD3 mAb induced themRNAs for p55 IL-2 receptor, IFN--y, and
IL-2 (Fig . 6) . With Con A stimulation, lymphokine mRNA appeared as early as
5 h, and peaked at 24 h (data not shown) .
We next monitored the effects of CSA on lymphokine gene expression in vivo .
CSA strongly blocked the induction of IFN-,y and IL-2 mRNA but only partially
blocked the induction of the p55 IL-2 receptor message (Figs. 6 and 7) . Taken to-
FIGURE 6 .
￿
Effect ofCSAon lympho-
kine mRNA expression . Two experi-
ments in which syngeneic (CxD2FI) or
allogeneic (B6xD2F1) spleen cells (107)
were injected into the hind footpads of
CxD2 mice that were or were not im-
munosuppressed with CSA. After 24
h for IL-2 and IFN, and 48 h for IL-
2R,lymphnodes were collected . Total
RNA was extracted and separated on
1% agarose-formaldehyde gel and hy-
bridized with 32P-labeled probes.
FIGURE 7 .
￿
Effect ofCSAon lymphokinemRNA expression . Anti-
CD3 mAb (2C11) ascites fluid (30 pl) or ConA (50 jug) was in-
jected into the hind footpads ofCSA or non-CSA treated mice .
After 24 h for IL-2 and IFN, and 48 h for IL-2R, lymph nodes
were collected. Total RNA was extracted and separated on 1
agarose-formaldehyde gel and hybridized with 32P-labeled probes .540 CYCLOSPORIN A EFFECTS IN VIVO
FIGURE 8 . Treatment with CSA in vivo inhibits lymphokine
mRNA on in vitro-stimulated spleen cells. Spleen cells obtained
from mice that were or were not immunosuppressed with CSA
were left unstimulated or stimulated in vitro with ConA (5,ug/ml)
and PMA (5 ng/ml). After 5 hRNA was extracted separated on
agarose-formaldehyde gel and hybridized with 32P-labeled probes .
TABLE III
In Situ Hybridization for IL-2, IL-2R, and IFN-y mRNAs
Allogeneic spleen cells (10 7 ) were injected in the hind foot pads ofmice treated
or not with CSA (30 mg/kg/day) . At the indicated times, the draining lymph
nodes were removed and cell suspensions were prepared . Cells were cytospun
and analyzed formRNAs by in situ hybridization . The numbers represent the
percentage of labeled cells . Cells with more than 10 grains were scored as posi-
tive . Background was 2.4 grains per cell .
gether, these results show that in vivo stimulation with allogeneic cells or mitogens
induces severalT cell activation genes, and this induction is greatly reducedby CSA.
To evaluate the reversibility ofCSA, we administered the drug in vivo on three
consecutive days and thenremoved spleen cells to test theirresponse to a subsequent
challenge ofmitogen in vitro. Immediatelyupon isolation, the cellswere less respon-
sive to the inducing effects of mitogen (Fig . 8), i.e ., the induction of IFN-'r or IL-2
mRNA was decreased N20-fold . However this inhibition was short lived . If the cells
were cultured for 20 h before challenge, the cells from CSA-treated animals showed
no block in the induction of IL-2 mRNA . Therefore, CSA seems to partially block
the response ofT cells from CSA-treated mice to mitogens in vitro, but this block
is rapidly reversible.
Frequency of Cells ExpressingActivation GenesIn Viva
￿
In situ hybridizationwasused
Time Allo
IL-2
Allo-CSA Allo
IFN-y
Alto-CSA Allo
IL-2R
Allo-CSA
h % %
7 0 ND ND ND ND ND
16 0 .8 0 .2 ND ND ND ND
24 2 .5 0 .7 3.5 0 .11 0 .9 0 .8
36 2 .0 0 .4 2 .1 0.16 4 .6 3.3
48 0 0 0 .7 0 5 .9 4.0GRANELLI-PIPERNO
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to identifycells expressing T cell activation genes atthe single celllevel. After injec-
tion ofallogeneiccells, we monitoredtranscripts bothondispersedlymphnode cells
or in lymph node sections. IL-2 and IFN-y transcripts peaked at 24-36 h, while
IL-2 receptor transcripts appeared later and were more evident at 48 h (Table III).
2-4% ofthe cells were labeled at the peakofthe response with lymphokine probes,
and4-6% withtheIL-2 receptor probe (Table III). Administration ofCSA reduced
the numberofcells that were inducedtoexpress lymphokine, but not IL-2 receptor,
genes (Table III).
Discussion
Studies in tissue culture have identified several molecular events that are altered
in theimmunologically stimulated Tlymphocyte. Nolessthan 70 genesare reported
to be induced (3, 4). We have used single cell and molecularapproaches to monitor
some ofthe main parametersofT cell activation in situ, i.e., upon challenge ofmice
with foreign cells orwith mitogens. Our results show that several mRNAs that un-
derlie T cell function can be induced in vivo. These are the mRNAs for the lym-
phokines IL-2 and IFN-y, and forthe low a$mity IL-2 receptor. High affinity IL-2
receptorsare also present inmicechallenged with foreign cells, since there is alarge
increase inthe responsiveness ofthe draininglymph nodeto verylowdosesofexoge-
nousIL-2 (Fig. 1). The number ofcellswithlymphokine transcriptsdoesnot exceed
2-3% in theresponse to alloantigen, while somewhat higher percentages, N5%, ex-
press the p55 IL-2 receptor mRNA at the assay times we tested. Prior work has
shown that a polyclonal neutralizing antibody to IL-2 can block T cell responses
in situ and in vitro (13). Taken together then, many ofthe molecular events that
are occurring in tissue culture also occur in vivo upon challenge with foreignleuko-
cytes and mitogens.
The area in whichthere seems to be a discrepancybetween events in tissue culture
and experimental animals pertains to the mechanism ofaction ofthe immunosup-
pressivedrug CSA. There are reports that indicate that CSA does not block certain
parameters ofT cell activation in situ (10, 11, 22) and that DNA synthesis still pro-
ceeds normally in response to alloantigen (10). Yet in vitro, the block in DNA syn-
thesis that is induced by CSA is profound (1, 21, 23-26). The latter primarily in-
volves ablockintheinductionoflymphokine mRNAsandnotablockin.theacquisition
of IL-2 responsiveness (1, 21, 27). To a large extent, my findings indicate that the
action ofCSAinvivoissimilarto its action in vitro. There isablock inthe induction
ofboth IL-2 and IFN-ymRNAs, and there arereducednumbersofcellssynthesizing
DNA. These changes can be visualized in tissue sections of the stimulated lymph
node and in freshly prepared cell suspensions. When mitogens instead of alloan-
tigens are used as stimuli in vivo, I likewise observe that CSA reduces lymphokine
gene expression and DNA synthesis (Table II) and again CSA does not block the
induction of IL-2 responsiveness (Fig. 1).
The principalunknown therefore is to explain the fact that the reduction in DNA
synthesis in vivo is less complete than in vitro. This could reflect the existence of
a CSA-resistant IL-2 induction pathway. One such pathway entails the stimulation
of T cells with anti-CD28 mAb (20, 28). The physiologic ligand for CD28 is not
yetknown, and arecent report suggests that anti-CD28 increaseslymphokine mRNAs
at the level ofmRNA stability rather than induction oftranscription (29). Another542
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possibility is that there are CSA-resistant, IL-2-independent mechanisms for T cell
growth. IL-2 independence issometimesdifficult to establish. For example, it seemed
that T cells stimulated with anti-CD3 mAb and monocytes did not produce IL-2
(30), yet a role for IL-2 was apparent when poly(A) mRNA rather than total RNA
was used to detect the IL-2 transcripts, or when anti-IL-2 receptor antibody was
used to block DNA synthesis (31). Other growth factors like IL-4 are known, but
to date these are sensitive to CSA (32). A third possibility is that in mice the clear-
ance or catabolism of CSA is rapid, and/or the drug does not gain as ready access
to T cells. Given the fact that the effects ofCSA are rapidly reversible, it may be
difficult to achieve adequate levels of the drug continuously in lymphoid organs .
It is of interest that the dose ofCSA that must be given to mice is high relative to
that used clinically. In our experiments, we had to achieve serum levels ofclose to
1 Fig/ml to detect immunosuppression at the level ofthe draining lymph node, i.e.,
intheinduction ofalloreactive CTL. Inpatients, serumlevels of100 ng/ml are sufficient
to maintain immunosuppression.
Therefore, the data in this article indicate that CSA can influence lymphokine
gene expression in mice asit does in tissue culture systems, and does so rather selec-
tively when compared with the lack ofan effect on the acquisition of IL-2 respon-
siveness. However, it is not yet clear ifthe block in lymphokine gene expression is
sufficient to account for suppression of immune responses in vivo (23, 24, 33-35)
or if there are additional pathways that remain to be identified.
Summary
Murine Tcellswere stimulatedin vivoby administering allogeneic cells ormitogens
intothe footpads andthenexamining the draining popliteallymphnodes. Allogeneic
spleen cells induced the expression ofIL2 and IFN--y mRNAs in a time- and dose-
dependent manner. Induction ofthese transcripts also was detected after adminis-
tration of Con A and anti-CD3 mAb. An increase in DNA-synthesizing cells was
observed by 48 h, and these were shown to be T cells because of their sensitivity
to antiThy-1 but not anti-B220 mAb and complement, and because of their local-
ization to the T -dependent areas of the lymph node.
The in vivo administration ofcyclosporin A (CSA) reduced several ofthese T cell
responses. The level ofDNA synthesis andthe frequency ofcells synthesizing DNA
were decreased by -75%, while the induction of IL-2 responsiveness was not sub-
stantially diminished. IL-2 and IFN-,y transcripts were inhibited at least 70-90%,
as determined by Northern blot and in situ hybridization. Although the inhibition
by CSA was not as complete in animals as observed previously in tissue culture,
our findings indicatethat inboth systems, a major site ofaction ofCSA is to inhibit
T cell growth by inhibiting lymphokine production.
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